Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research

키워드

참고문헌 (69)

1. Nestler EJ, "Animal models of neuropsychiatric disorders", Nat Neurosci, 13, pp.1161~1169 (2010)
2. Takahashi K, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", Cell, 126, pp.663~676 (2006)
3. Gonzalez F, "Methods for making induced pluripotent stem cells : reprogramming a la carte", Nat Rev Genet, 12, pp.231~242 (2011)
4. Takahashi K, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", Cell, 131, pp.861~872 (2007)
5. Swistowski A, "Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions", Stem Cells, 28, pp.1893~1904 (2010)
6. Tran NN, "Modeling schizophrenia using induced pluripotent stem cell-derived and fibroblast-induced neurons", Schizophr Bull, 39, pp.4~10 (2013)
7. Aasen T, "Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes", Nat Biotechnol, 26, pp.1276~1284 (2008)
8. Brown ME, "Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes", PLoS One, 5, pp.e11373~ (2010)
9. Seki T, "Derivation of induced pluripotent stem cells from human peripheral circulating T cells", Curr Protoc Stem Cell Biol (2011)
10. Zhou T, "Generation of induced pluripotent stem cells from urine", J Am Soc Nephrol, 22, pp.1221~1228 (2011)
11. Zhou T, "Generation of human induced pluripotent stem cells from urine samples", Nat Protoc, 7, pp.2080~2089 (2012)
12. Fusaki N, "Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome", Proc Jpn Acad Ser B Phys Biol Sci, 85, pp.348~362 (2009)
13. Phelan K, "The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)", Mol Syndromol, 2, pp.186~201 (2012)
14. Shcheglovitov A, "SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients", Nature, 503, pp.267~271 (2013)
15. Splawski I, "2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism", Cell, 119, pp.19~31 (2004)
16. Pasca SP, "Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome", Nat Med, 17, pp.1657~1662 (2011)
17. Krey JF, "Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons", Nat Neurosci, 16, pp.201~209 (2013)
18. Chahrour M, "The story of Rett syndrome : from clinic to neurobiology", Neuron, 56, pp.422~437 (2007)
19. Amir RE, "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2", Nat Genet, 23, pp.185~188 (1999)
20. Scala E, "CDKL5", STK9 is mutated in Rett syndrome variant with infantile spasms, 2005, pp.42, 103~107
21. Ariani F, "FOXG1 is responsible for the congenital variant of Rett syndrome", Am J Hum Genet, 83, pp.89~93 (2008)
22. Marchetto MC, "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells", Cell, 143, pp.527~539 (2010)
23. Farra N, "Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations", Mol Psychiatry, 17, pp.1261~1271 (2012)
24. Tanaka Y, "Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2(MeCP2)", Hum Mol Genet, 23, pp.1045~1055 (2014)
25. Larimore J, "MeCP2 regulates the synaptic expression of a Dysbindin-BLOC-1 network component in mouse brain and human induced pluripotent stem cell-derived neurons", PLoS One, 8, pp.e65069~ (2013)
26. Williams EC, "Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons", Hum Mol Genet, 23, pp.2968~2980 (2014)
27. Amenduni M, "iPS cells to model CDKL5-related disorders", Eur J Hum Genet, 19, pp.1246~1255 (2011)
28. Lewis DA, "Catching up on schizophrenia : natural history and neurobiology", Neuron, 28, pp.325~334 (2000)
29. Krishnan RR, "Schizophrenia is a disorder of higher order hierarchical processing", Med Hypotheses, 72, pp.740~744 (2009)
30. White T, "The schizophrenia prodrome", Am J Psychiatry, 163, pp.376~380 (2006)
31. Insel TR, "Rethinking schizophrenia", Nature, 468, pp.187~193 (2010)
32. Ryan J, "Crucial timing in schizophrenia : role of DNA methylation in early neurodevelopment", Genome Biol, 15, pp.495~ (2014)
33. Brennand KJ, "Modelling schizophrenia using human induced pluripotent stem cells", Nature, 473, pp.221~225 (2011)
34. Brennand K, "Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia", Mol Psychiatry, 20, pp.361~368 (2015)
35. Paulsen Bda S, "Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient", Cell Transplant, 21, pp.1547~1559 (2012)
36. Paulsen Bda S, "Valproate reverts zinc and potassium imbalance in schizophrenia-derived reprogrammed cells", Schizophr Res, 154, pp.30~35 (2014)
37. Robicsek O, "Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients", Mol Psychiatry, 18, pp.1067~1076 (2013)
38. Yu DX, "Modeling hippocampal neurogenesis using human pluripotent stem cells", Stem Cell Reports, 2, pp.295~310 (2014)
39. Barnett JH, "The genetics of bipolar disorder", Neuroscience, 164, pp.331~343 (2009)
40. Schneider MR, "Neuroprogression in bipolar disorder", Bipolar Disord, 14, pp.356~374 (2012)
41. Chen HM, "Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients", Transl Psychiatry, 4, pp.e375~ (2014)
42. Selkoe DJ, "Alzheimer’s disease", Cold Spring Harb Perspect Biol, 3 (2011)
43. Dickson DW, "Neuropathology of Alzheimer’s disease and other dementias", Clin Geriatr Med, 17, pp.209~228 (2001)
44. Hardy J, "The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
45. Abeliovich A, "Reprogramming therapeutics : iPS cell prospects for neurodegenerative disease", Neuron, 61, pp.337~339 (2009)
46. Yagi T, "Modeling familial Alzheimer’s disease with induced pluripotent stem cells", Hum Mol Genet, 20, pp.4530~4539 (2011)
47. Kondo T, "Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness", Cell Stem Cell, 12, pp.487~496 (2013)
48. Woodruff G, "The presenilin-1 ΔE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells", Cell Rep, 5, pp.974~985 (2013)
49. Israel MA, "Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells", Nature, 482, pp.216~220 (2012)
50. Hargus G, "Human stem cell models of neurodegeneration : a novel approach to study mechanisms of disease development", Acta Neuropathol, 127, pp.151~173 (2014)
51. Snowden JS, "Frontotemporal dementia", Br J Psychiatry, 180, pp.140~143 (2002)
52. Rademakers R, "Advances in understanding the molecular basis of frontotemporal dementia", Nat Rev Neurol, 8, pp.423~434 (2012)
53. Bilican B, "Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability", Proc Natl Acad Sci U S A, 109, pp.5803~5808 (2012)
54. Serio A, "Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy", Proc Natl Acad Sci U S A, 110, pp.4697~4702 (2013)
55. Zhang Z, "Downregulation of microRNA-9 in iPSC-derived neurons of FTD", ALS patients with TDP-43 mutations, 2013, pp.8, e76055~
56. Almeida S, "Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects", Cell Rep, 2, pp.789~798 (2012)
57. Fong H, "Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells", Stem Cell Reports, 1, pp.226~234 (2013)
58. Almeida S, "Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons", Acta Neuropathol, 126, pp.385~399 (2013)
59. Donnelly CJ, "RNA toxicity from the ALS", FTD C9ORF72 expansion is mitigated by antisense intervention, 2013, pp.80, 415~428
60. Sareen D, "Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion", Sci Transl Med, 5, pp.208ra149~ (2013)
61. Brian TD Tobe, "Implications and limitations of cellular reprogramming for psychiatric drug development", Experimental and Molecular Medicine, 45, pp.1~11 (2013), 생화학분자생물학회
62. Brennand KJ, "Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells", Biol Psychiatry, 75, pp.936~944 (2014)
63. Chiang CH, "Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation", Mol Psychiatry, 16, pp.358~360 (2011)
64. Vierbuchen T, "Direct conversion of fibroblasts to functional neurons by defined factors", Nature, 463, pp.1035~1041 (2010)
65. Pang ZP, "Induction of human neuronal cells by defined transcription factors", Nature, 476, pp.220~223 (2011)
66. Caiazzo M, "Direct generation of functional dopaminergic neurons from mouse and human fibroblasts", Nature, 476, pp.224~227 (2011)
67. Sandoe J, "Opportunities and challenges of pluripotent stem cell neurodegenerative disease models", Nat Neurosci, 16, pp.780~789 (2013)
68. Boissart C, "Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening", Transl Psychiatry, 3, pp.e294~ (2013)
69. Becker RE, "Lost in translation: neuropsychiatric drug development", Sci Transl Med, 2, pp.61rv6~ (2010)

관련 논문AI추천